Alnylam Pharmaceuticals' Revenue rose 149.35% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 billion, marking a year-over-year increase of 26.31%. This contributed to the annual value of $2.2 billion for FY2024, which is 22.97% up from last year.
According to the latest figures from Q3 2025, Alnylam Pharmaceuticals' Revenue is $1.2 billion, which was up 61.44% from $773.7 million recorded in Q2 2025.
Alnylam Pharmaceuticals' 5-year Revenue high stood at $1.2 billion for Q3 2025, and its period low was $30.0 million during Q1 2025.
For the 3-year period, Alnylam Pharmaceuticals' Revenue averaged around $557.2 million, with its median value being $500.9 million (2024).
As far as peak fluctuations go, Alnylam Pharmaceuticals' Revenue surged by 183.96% in 2023, and later plummeted by 93.93% in 2025.
Over the past 5 years, Alnylam Pharmaceuticals' Revenue (Quarterly) stood at $258.5 million in 2021, then increased by 29.59% to $335.0 million in 2022, then spiked by 31.25% to $439.7 million in 2023, then spiked by 34.90% to $593.2 million in 2024, then spiked by 149.35% to $1.2 billion in 2025.
Its Revenue stands at $1.2 billion for Q3 2025, versus $773.7 million for Q2 2025 and $30.0 million for Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value